| Identification | Back Directory | [Name]
Sasapyrine | [CAS]
552-94-3 | [Synonyms]
diagen
Salina
Salysal
Disalyl
Nobacid
Salical
salflex
salgesic
salsitab
Arcylate
Saloxium
disalcid
amigesic
Diacesal
Diplosal
Sasapirin
Sasapyrin
NSC-49171
SALSALATE
SASAPYRINE
mono-gesic
Disalgesic
Sasapyrinum
Sal Ester Sal
disalicylicacid
Disalicylic acid
Double salicylate
Salsalate (150 mg)
Salsalate (125 mg)
Aspirin IMpurity E
Aspirin Impurity 5
Salicyl-salicylate
SALSALATE USP XXIV
TIMTEC-BB SBB003097
SALICYLSALICYLIC ACID
Aspirin EP IMpurity E
O-SALICYLSALICYLIC ACID
salicylylsalicylic acid
2-salicylsalicylic acid
salicyloylsalicylicacid
Salicyloxysalicylic acid
Salicyloylsalicylic acid
Salicylsalicylicacid,98%
Salicylsalicylic acid,99%
SALICYLIC ACID SALICYLATE
SALICYLSALICYLIC ACID 99%
O-SALICYLOYLSALICYLIC ACID
2-CARBOXYPHENYL SALICYLATE
2-SALICYLOYLOXYBENZOIC ACID
DISALICYLIC ACID, SALSALATE
Sasapyrine Solution, 100ppm
Salicylic acid, bimol. ester
Salicylic acid 2-carboxyphenyl
Salsalate (Aspirin Impurity E)
salicylicacid,bimolecularester
Salicylic acid, bimolecular ester
2-[(2-Hydroxybenzoyl)oxy]benzoic acid
2-hydroxy-benzoicaci2-carboxyphenylester
2-HYDROXYBENZOIC ACID 2-CARBOXYPHENYL ESTER
2-[(2-hydroxyphenyl)carbonyloxy]benzoic acid
Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester
Acetylsalicylic Acid IMpurity E (Aspirin IMpurity E)
2-HYDROXYBENZOICACID-2-CARBOXYPHENYLESTER(SALSALATE)
2-Salicyloyloxybenzoic Acid
O-Salicyloylsalicylic Acid
Salicylic Acid 2-Carboxyphenyl Ester
Salsalate | [EINECS(EC#)]
209-027-4 | [Molecular Formula]
C14H10O5 | [MDL Number]
MFCD00020252 | [MOL File]
552-94-3.mol | [Molecular Weight]
258.23 |
| Hazard Information | Back Directory | [Chemical Properties]
white crystalline powder | [Uses]
Nonacetylated aspirin analog. Analgesic, anti-inflammatory. | [Definition]
ChEBI: A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthrit
s and also shows activity against type II diabetes. | [Uses]
Nonacetylated (e.g., sodium salicylate) and acetylated (aspirin) forms of salicylate are widely used to target inflammation in the treatment of insulin resistance, type 2 diabetes, or rheumatic pain. Salsalate is a dimeric prodrug comprising two esterified salicylate moieties. It is advantageous over sodium salicylate because it is insoluble at the acid pH of the stomach and passes suspended but undissolved into the small intestine, sparing the gastric mucosa direct contact. Proof-of-principle clinical studies demonstrate that 3-4.5 g/d salsalate can reduce blood glucose, triglyceride, free fatty acid and C-reactive protein concentrations, improve glucose utilization, and increase circulating insulin and adiponectin concentrations in obese adults at risk for the development of type 2 diabetes as well as for patients with type 2 diabetes. | [Description]
Salsalate, or salicylsalicylic acid, (pKa 3.5 [COOH], 9.8 [AR-OH]) is a dimer of salicylic acid. It is insoluble in gastric
juice but is soluble in the small intestine, where it is partially hydrolyzed to two molecules of salicylic acid and
absorbed. On a molar basis, it produces 15% less salicylic acid than aspirin. It does not cause GI blood loss and can
be given to aspirin-sensitive patients. Salsalate is available as capsules and tablets. | [Brand name]
Disalcid (3M Pharmaceuticals). | [General Description]
Salsalate, salicylsalicylic acid (Amigesic, Disalcid,Salflex), is the ester formed between two salicylic acidmolecules. It is rapidly hydrolyzed to salicylic acid followingits absorption. It reportedly causes less gastric irritationthan aspirin, because it is relatively insoluble inthe stomach and is not absorbed until it reaches the smallintestine. | [Biochem/physiol Actions]
Salsalate is a nonsteroidal anti-inflammatory drug (NSAID), a nonacetylated salicylate with no more problems of gastrointestinal bleeding than placebo. It inhibits synthesis and release of prostaglandins through the inactivation of cyclooxygenase-1 (COX-1) and COX-2. Salsalate is currently being investigated as a treatment for Type 2 diabetes with possible use to prevent the disease in people at risk. It reduces blood glucose concentrations in patients with type 2 diabetes, as well as in insulin-resistant patients without diabetes. | [storage]
Store at -20°C |
|
|